Last reviewed · How we verify

Vegf Trap biosimilars

Complete Vegf Trap (AFLIBERCEPT) biosimilar landscape: 12 approved biosimilars, 0 filed, 3 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

12 approved 0 filed 3 Phase 3 All key patents expired

About Vegf Trap

Vegf Trap (AFLIBERCEPT) — originally marketed by Regeneron. Class: Vascular Endothelial Growth Factor Inhibitor. Target: Vascular endothelial growth factor A. Area: Oncology. First approved 2011-01-01.

Approved biosimilars (12)

BiosimilarSponsorPhaseFirst approvalCountry
Aflibercept Injection [Eylea] Caregen Co. Ltd. marketed
Aflibercept Injection Federation Francophone de Cancerologie Digestive marketed
Aflibercept Intravitreous Injection Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine marketed
Aflibercept (Eylea) Ahmad Zeeshan Jamil marketed
Aflibercept and ranibizumab Instituto de Olhos de Goiania marketed
PAVBLU AMGEN INC marketed
YESAFILI BIOCON BIOLOGICS INC marketed
AHZANTIVE FORMYCON AG marketed
ENZEEVU SANDOZ INC marketed
OPUVIZ SAMSUNG BIOEPIS CO LTD marketed
aflibercept + FOLFIRI CR-CSSS Champlain-Charles-Le Moyne marketed
EYDENZELT CELLTRION INC marketed

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (3)

BiosimilarSponsorPhaseFirst approvalCountry
aflibercept 8 mg Yeungnam University College of Medicine phase 3
Aflibercept (Regeneron, USA) Cinnagen phase 3
Aflibercept-mFOLFIRI3 Hôpital Franco-Britannique-Fondation Cognacq-Jay phase 3

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

Subscribe to biosimilar updates

Every regulatory action on Vegf Trap or any of its biosimilars:

Related